Please login to the form below

Not currently logged in
Email:
Password:

Boehringer in antibody partnership

Boehringer Ingelheim has signed a deal with MacroGenics to develop therapies based on MacroGenics' antibody technology platform

Boehringer Ingelheim has signed a deal with the privately held biotechnology company MacroGenics to develop and commercialise therapies based on MacroGenics' antibody technology platform.

Under the global alliance, the companies will work together to discover, develop and commercialise therapeutics in areas such as immunology, oncology, respiratory, cardiometabolic and infectious diseases. The drug candidates will be based on MacroGenics' Dual-Affinity Re-Targeting (DART) biospecific antibody technology platform and will be directed against up to 10 combinations of molecular targets.

The companies will have joint responsibility for discovery and some preclinical activities, with Boehringer Ingelheim taking full responsibility for all subsequent preclinical, clinical, regulatory, commercial and manufacturing activities.

MacroGenics will likely receive about $60m during the first several years of the partnership, with that figure consisting of an upfront cash payment, annual maintenance fees, R&D funding, and near-term research-based milestones. The company also stands to receive milestone payments that could theoretically total $210m for each of the 10 development programmes in case of full commercial success of multiple DART products.

The deal calls for MacroGenics to receive tiered royalties on net product sales and gives the company the option to co-promote certain DART products in the US. In addition, as the partnership progresses, Boehringer Ingelheim also expects to make an equity investment in the company.

MacroGenics, which was founded about a decade ago, is based in Rockville, Maryland. The company's lead product is teplizumab, an antibody that is in phase III trials for the treatment of autoimmune diseases under a partnership with Lilly.

27th October 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics